Skip Nav Destination
1-3 of 3
Biochem Soc Trans (2020) 48 (3): 1287–1295.
Published: 08 June 2020
... until effective therapeutics and a vaccine are available. The immediacy of this problem suggests that drug strategies should focus on repurposing approved drugs or late-stage clinical candidates, as these have the shortest path to use in the clinic. Here, we review and discuss the role of host cell N...
Biochem Soc Trans (2008) 36 (6): 1197–1200.
Published: 19 November 2008
... diseases, such as viral infections, cancer and cardiovascular diseases, and thus miRNAs have rapidly emerged as potential targets for therapeutics. LNAs (locked nucleic acids) comprise a class of bicyclic conformational analogues of RNA, which exhibit high binding affinity to complementary RNA molecules...
Biochem Soc Trans (2003) 31 (2): 433–436.
Published: 01 April 2003
...L.H. Stockwin; S. Holmes The last 5 years have seen a major upturn in the fortune of therapeutic monoclonal antibodies (mAbs), with nine mAbs approved for clinical use during this period and more than 70 now in clinical trials beyond phase II. Sales are expected to reach $4 billion per annum...